A predictive and prognostic biomarker profile of carcinoma breast

Context: The immunohistochemical (IHC 4) biomarker profile is part of the standard histopathology reportof all newly diagnosed and recurrent cases of carcinoma Breast. This profile is the basis for all neoadjuvantand adjuvant treatment planning in these cases.Aims: 1. To study the IHC4 biomarker profile of Carcinoma Breast cases at our Institute.2. To study the correlation of the five types of molecular subgroups with various clinical and histologicalparameters.Settings and Design: 271 cases of carcinoma breast diagnosed and treated at our Institute, during theperiod 1st July 2017 till 30th June 2018.This is a prospective, observational study.Materials and Methods: All the cases of biopsy proven carcinoma Breast were subjected toimmunohistochemical staining for four markers- ER, PR, Her 2, and Ki 67.Fo rmalin Fixed Paraffin Embedded tumor tissue was stained for 4 biomarkers and scored with appropriatemethod. (Interpretive Guide: ASCO - CAP Test Guidelines Recommendations 2013)Manual method of staining was employed, using commercially available reagents.The cases were classified into five molecular subtypes.Results: Triple negative breast carcinoma was the most frequent subgroup, followed by the luminal B andA types and the Her2 enriched cases were lowest in number.A few cases showed triple positive staining pattern.Conclusions: The IHC 4 biomarker findings in every case of carcinoma has a direct impact on the treatmentdecision making and also on risk stratification of the patients.Keywords: IHC 4, ER, PR, Her2, Ki67, Carcinoma breast.